GTX Inc (GTXI) 1.21 $GTXI
GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014
Business Wire - Tue Jul 22, 6:30AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the date for its second quarter 2014 financial results press release will be Tuesday, August 5, 2014, prior to the opening of the U.S. stock markets. Similar to the previous quarter, the Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Wed Jul 02, 7:18AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Corneal Neovascularization - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lld3cs/corneal) has announced the addition of the "Corneal Neovascularization - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Neovascularization and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Corneal Neovascularization - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Corneal Neovascularization and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - F. Hoffmann-La Roche Ltd. - GTx, Inc. - Sirnaomics, Inc. - Amakem NV For more information visit http://www.researchandmarkets.com/research/lld3cs/corneal
Stock to Watch: GTx Down 10.2% (GTXI)
Comtex SmarTrend(R) - Mon Jun 02, 10:09AM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 10.2% to $1.49 on 1.5x average daily volume. GTx has traded 618,000 shares thus far today, vs. average volume of 406,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's -0.0%) and underperformed the S&P 500 (-10.2% to the S&P's -0.2%) during today's trading.
GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer
Business Wire - Mon Jun 02, 10:01AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy. The clinical data is being presented today during the Breast Cancer-HER2/ER poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
GTX Inc. (GTXI) Soars: Stock Up 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 29, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose nearly 10% on the day.
Morning Briefing on Top Gainers -- Research on GTx Inc., Iridium Communications, Neuralstem, and Idera Pharma
PR Newswire - Thu May 29, 5:50AM CDT
The US markets saw a negative sentiment on Wednesday, May 28, 2014, with the NASDAQ Composite closing at 4,225.08, down 0.28%, the Dow Jones Industrial Average ending the session at 16,633.18, down 0.25% and the S&P 500 finishing 0.11% lower at 1,909.78. During the trading session, five out of ten sectors finished on a lower note. Investor-Edge has initiated coverage on the following equities: GTx Inc. (NASDAQ: GTXI), Iridium Communications Inc. (NASDAQ: IRDM), Neuralstem Inc. (NYSE MKT: CUR) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on GTXI, IRDM, CUR and IDRA can be downloaded upon signing up at:
Traders Get Bullish on Shares of GTx, Shares Up 8.2% (GTXI)
Comtex SmarTrend(R) - Wed May 28, 10:40AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 8.2% to $1.56 on 1.7x average daily volume. GTx has traded 641,000 shares thus far today, vs. average volume of 388,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.2%) and outperformed the S&P 500 (8.2% to the S&P's -0.0%) during today's trading.
GTx Announces Webcast of Corporate Presentation at Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 22, 6:30AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 4, 2014, at the Jefferies 2014 Global Healthcare Conference in New York City. The GTx presentation will begin at 1:30 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 18.
GTx Down 7.9%, Shares Slide into the Red (GTXI)
Comtex SmarTrend(R) - Thu Mar 27, 12:45PM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.9% to $1.51 on 1.4x average daily volume. Thus far today, GTx has traded 874,000 shares, vs. average volume of 604,000 shares per day. The stock has underperformed the Dow (-7.9% to the Dow's -0.1%) and underperformed the S&P 500 (-7.9% to the S&P's -0.3%) during today's trading.
Strength Seen in GTX (GTXI): Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:46AM CDT
GTX was a big mover last session, with shares rising nearly 9% on the day.
GTx Up 8.5%, Shares Break Through Resistance (GTXI)
Comtex SmarTrend(R) - Thu Mar 13, 10:17AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 8.5% to $1.91 on 2.5x average daily volume. GTx has traded 1.3 million shares thus far today, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's -0.2%) and outperformed the S&P 500 (8.5% to the S&P's -0.2%) during today's trading.
GTx, Inc. Announces Closing of Private Placement
Business Wire - Thu Mar 06, 4:05PM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx issued 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 newly-issued shares of common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The purchasers consisted of J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation. Gross proceeds from the offering were approximately $21.3 million.
Narrower-than-Expected Q4 Loss at GTx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:50AM CST
GTx, reported fourth quarter 2013 net loss per share of 12 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents
GTx Announces Webcast of Corporate Presentation at 26TH Annual ROTH Conference
Business Wire - Wed Mar 05, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 11, 2014 at the 26th Annual ROTH Conference in Dana Point, CA. The GTx presentation will begin at 1:00 p.m. EDT. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 25, 2014.
GTx Provides Corporate Update and Reports 2013 Financial Results
Business Wire - Tue Mar 04, 6:00AM CST
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.
GTx, Inc. Announces Pricing of Private Placement
Business Wire - Tue Mar 04, 5:30AM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it has entered into a securities purchase agreement with J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation, to issue and sell in a private placement to these purchasers an aggregate of 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 shares of GTx common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The total purchase price payable to GTx for the units is $21,272,455.42, or approximately $1.77625 per unit. The warrants, which may only be exercised for cash, will have a per share exercise price of $1.67 (equal to the closing bid price of GTx's common stock on March 3, 2014) and a one year term. The closing of the private placement will occur three business days following the satisfaction or waiver of customary closing conditions as set forth in the securities purchase agreement, or on such other date as the purchasers in the private placement may agree upon. The securities purchase agreement will terminate if the closing of the private placement has not occurred on or prior to April 15, 2014, provided that the purchasers in the private placement may, in their sole discretion, extend such date to August 15, 2014.
GTx Announces Webcast of Corporate Presentation at Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 5, 2014 at the Cowen and Company 34th Annual Health Care Conference in Boston. The GTx presentation will begin at 8.00 a.m. EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 19, 2014.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014
Business Wire - Tue Jul 22, 6:30AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the date for its second quarter 2014 financial results press release will be Tuesday, August 5, 2014, prior to the opening of the U.S. stock markets. Similar to the previous quarter, the Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Wed Jul 02, 7:18AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Corneal Neovascularization - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lld3cs/corneal) has announced the addition of the "Corneal Neovascularization - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Neovascularization and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Corneal Neovascularization - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Corneal Neovascularization and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - F. Hoffmann-La Roche Ltd. - GTx, Inc. - Sirnaomics, Inc. - Amakem NV For more information visit http://www.researchandmarkets.com/research/lld3cs/corneal
Stock to Watch: GTx Down 10.2% (GTXI)
Comtex SmarTrend(R) - Mon Jun 02, 10:09AM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 10.2% to $1.49 on 1.5x average daily volume. GTx has traded 618,000 shares thus far today, vs. average volume of 406,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's -0.0%) and underperformed the S&P 500 (-10.2% to the S&P's -0.2%) during today's trading.
GTx Reports Positive Clinical Data from Open Label Phase 2 Study of Enobosarm in Patients with Androgen and Estrogen Receptor Positive Metastatic Breast Cancer
Business Wire - Mon Jun 02, 10:01AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy. The clinical data is being presented today during the Breast Cancer-HER2/ER poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
GTX Inc. (GTXI) Soars: Stock Up 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 29, 7:51AM CDT
GTX Inc. (GTXI) was a big mover last session, as its shares rose nearly 10% on the day.
Morning Briefing on Top Gainers -- Research on GTx Inc., Iridium Communications, Neuralstem, and Idera Pharma
PR Newswire - Thu May 29, 5:50AM CDT
The US markets saw a negative sentiment on Wednesday, May 28, 2014, with the NASDAQ Composite closing at 4,225.08, down 0.28%, the Dow Jones Industrial Average ending the session at 16,633.18, down 0.25% and the S&P 500 finishing 0.11% lower at 1,909.78. During the trading session, five out of ten sectors finished on a lower note. Investor-Edge has initiated coverage on the following equities: GTx Inc. (NASDAQ: GTXI), Iridium Communications Inc. (NASDAQ: IRDM), Neuralstem Inc. (NYSE MKT: CUR) and Idera Pharmaceuticals Inc. (NASDAQ: IDRA). Free technical research on GTXI, IRDM, CUR and IDRA can be downloaded upon signing up at:
Traders Get Bullish on Shares of GTx, Shares Up 8.2% (GTXI)
Comtex SmarTrend(R) - Wed May 28, 10:40AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 8.2% to $1.56 on 1.7x average daily volume. GTx has traded 641,000 shares thus far today, vs. average volume of 388,000 shares per day. The stock has outperformed the Dow (8.2% to the Dow's -0.2%) and outperformed the S&P 500 (8.2% to the S&P's -0.0%) during today's trading.
GTx Announces Webcast of Corporate Presentation at Jefferies 2014 Global Healthcare Conference
Business Wire - Thu May 22, 6:30AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 4, 2014, at the Jefferies 2014 Global Healthcare Conference in New York City. The GTx presentation will begin at 1:30 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until June 18.
GTx Down 7.9%, Shares Slide into the Red (GTXI)
Comtex SmarTrend(R) - Thu Mar 27, 12:45PM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.9% to $1.51 on 1.4x average daily volume. Thus far today, GTx has traded 874,000 shares, vs. average volume of 604,000 shares per day. The stock has underperformed the Dow (-7.9% to the Dow's -0.1%) and underperformed the S&P 500 (-7.9% to the S&P's -0.3%) during today's trading.
Strength Seen in GTX (GTXI): Stock Moves 8.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:46AM CDT
GTX was a big mover last session, with shares rising nearly 9% on the day.
GTx Up 8.5%, Shares Break Through Resistance (GTXI)
Comtex SmarTrend(R) - Thu Mar 13, 10:17AM CDT
GTx (NASDAQ:GTXI) is one of today's best performing low-priced stocks, up 8.5% to $1.91 on 2.5x average daily volume. GTx has traded 1.3 million shares thus far today, vs. average volume of 506,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's -0.2%) and outperformed the S&P 500 (8.5% to the S&P's -0.2%) during today's trading.
GTx, Inc. Announces Closing of Private Placement
Business Wire - Thu Mar 06, 4:05PM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx issued 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 newly-issued shares of common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The purchasers consisted of J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation. Gross proceeds from the offering were approximately $21.3 million.
Narrower-than-Expected Q4 Loss at GTx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:50AM CST
GTx, reported fourth quarter 2013 net loss per share of 12 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents
GTx Announces Webcast of Corporate Presentation at 26TH Annual ROTH Conference
Business Wire - Wed Mar 05, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 11, 2014 at the 26th Annual ROTH Conference in Dana Point, CA. The GTx presentation will begin at 1:00 p.m. EDT. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 25, 2014.
GTx Provides Corporate Update and Reports 2013 Financial Results
Business Wire - Tue Mar 04, 6:00AM CST
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.
GTx, Inc. Announces Pricing of Private Placement
Business Wire - Tue Mar 04, 5:30AM CST
GTx, Inc. (NASDAQ: GTXI) announced today that it has entered into a securities purchase agreement with J.R. Hyde, III, the chairman of GTx's Board of Directors, and The Pyramid Peak Foundation, to issue and sell in a private placement to these purchasers an aggregate of 11,976,048 immediately separable units, comprised of an aggregate of 11,976,048 shares of GTx common stock and warrants to purchase up to 10,179,642 additional shares of common stock. The total purchase price payable to GTx for the units is $21,272,455.42, or approximately $1.77625 per unit. The warrants, which may only be exercised for cash, will have a per share exercise price of $1.67 (equal to the closing bid price of GTx's common stock on March 3, 2014) and a one year term. The closing of the private placement will occur three business days following the satisfaction or waiver of customary closing conditions as set forth in the securities purchase agreement, or on such other date as the purchasers in the private placement may agree upon. The securities purchase agreement will terminate if the closing of the private placement has not occurred on or prior to April 15, 2014, provided that the purchasers in the private placement may, in their sole discretion, extend such date to August 15, 2014.
GTx Announces Webcast of Corporate Presentation at Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on March 5, 2014 at the Cowen and Company 34th Annual Health Care Conference in Boston. The GTx presentation will begin at 8.00 a.m. EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until March 19, 2014.
Cancer Cachexia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 25, 2:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/smbrv3/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2013" report to their offering. 'Cancer Cachexia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cancer Cachexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Cachexia. Scope - A snapshot of the global therapeutic scenario for Cancer Cachexia. - A review of the Cancer Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cancer Cachexia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cancer Cachexia Overview Therapeutics Development Pipeline Products for Cancer Cachexia - Overview Drug Profiles enobosarm - Drug Profile anamorelin hydrochloride - Drug Profile Xilonix - Drug Profile macimorelin acetate - Drug Profile clazakizumab - Drug Profile anamorelin hydrochloride - Drug Profile (megestrol formoterol) - Drug Profile (etodolac propranolol) - Drug Profile OHR/AVR-118 - Drug Profile MT-102 - Drug Profile LY-2495655 - Drug Profile bimagrumab - Drug Profile IP-1510 - Drug Profile IP-1510 - Drug Profile dronabinol - Drug Profile tertomotide - Drug Profile Ghrelin Receptor Agonists - Drug Profile Drug Targeting Vps34 - Drug Profile L-379 - Drug Profile Activin Type IIB Receptor Antagonist - Drug Profile DCB-CA2 - Drug Profile Drug For Cancer Cachexia - Drug Profile Drug Targeting Glutaminase - Drug Profile Drugs For Cancer Cachexia - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Eli Lilly and Company Novartis AG Aphios Corporation GTx, Inc. AEterna Zentaris Inc. Helsinn Healthcare S.A. Alder Biopharmaceuticals Inc. Vicus Therapeutics, LLC Ohr Pharmaceutical Inc. KAEL-GemVax Co., Ltd. XBiotech USA, Inc. Acacia Pharma Ltd. PsiOxus Therapeutics, Ltd. Signablok, Inc Myomics, Inc. Sprint Bioscience AB Itis Pharmaceuticals Pty Ltd For more information visit http://www.researchandmarkets.com/research/sm...r_cachexia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
